New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 28, 2012
07:05 EDTRNNRexahn initiated with an Outperform at Burrill
Target $1.00. Burrill believes Rexahn’s pipeline in oncology and CNS disorders is undervalued.
News For RNN From The Last 14 Days
Check below for free stories on RNN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 18, 2014
09:03 EDTRNNRexahn completes enrollment in four dose groups in Supinoxin Phase I trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use